Chicago Clinical Trials Unit

描述（由申请人提供）：芝加哥临床试验单位（CCTU）是一个由5个临床研究中心（CRS）组成的联盟，将解决NIAID的3个优先临床研究领域：1）成人HIV治疗策略，包括HIV治愈、非感染性合并症以及肝炎和结核病的感染性合并症; 2）预防HIV的疫苗; 3）综合HIV预防策略。CCTU由五个经验丰富，科学生产力的CRS组成，这些CRS具有独特的定位，可以开发，实施和调整NIAID临床研究优先领域的临床研究优先事项。 CCTU拥有良好的业绩记录，并将通过积极参与各种风险和受艾滋病毒影响的社区，参与高影响，突破性的临床研究，有效管理资源以及对临床活动，实验室和药房的关键绩效监督来继续其生产力。CCTU包括CRS和人员，他们长期和富有成效地参与了三个研究网络;第四个-抗菌素耐药性-是这个联盟中的一个新网络。社区康复服务中心及其网络附属机构包括：西北大学（成人艾滋病毒治疗战略）;伊利诺伊大学芝加哥分校（预防艾滋病毒的疫苗，艾滋病毒综合预防）。拉什大学（成人艾滋病毒治疗战略）、芝加哥大学（艾滋病毒综合预防战略）和Trinity健康与保健中心（成人艾滋病毒治疗战略）。其中四个社区服务中心位于芝加哥，这是一个拥有950万人口的族裔和种族多样化的城市地区，是美国第三大都会区，也是主要的城市艾滋病毒中心之一。该提案的目的是：制定、实施和调整以下临床研究计划：1）成人艾滋病毒治疗战略网络，2）预防艾滋病毒疫苗网络，3）艾滋病毒综合预防战略网络，以及4）相关和高危艾滋病毒感染/受影响社区与CCTU临床研究人员的双向接触。CTU处于有利地位，可以接触到不同的人群，并为NIAID的研究议程做出重大贡献。 相关性：过去30年来，艾滋病毒/艾滋病研究取得了惊人的科学进步，这在很大程度上要归功于NIAID的临床试验单位进行的高影响力的治疗和预防研究。芝加哥CTU将继续对新出现的临床研究需求做出快速反应，吸引选民，并确定更有效的治疗和预防策略。

DESCRIPTION (provided by applicant): The Chicago Clinical Trials Unit (CCTU) is a consortium of five Clinical Research Sites (CRSs) which will address three priority clinical research areas of the NIAID: 1) adult HIV therapeutic strategies including HIV cure, noninfectious comorbidities, and infectious co-morbidities of hepatitis and tuberculosis; 2) vaccines to prevent HIV; and 3) integrated HIV prevention strategies. The CCTU consists of five highly experienced and scientifically productive CRSs that are uniquely positioned to develop, implement and adapt the clinical research priorities of the NIAID clinical research priority areas. The CCTU has a proven track record and will continue its productivity through active engagement with a diverse host of at risk and HIV-impacted communities, participation in high impact, ground-breaking clinical research studies, efficient management of resources and critical performance oversight of the clinical activities, laboratories, and pharmacies. The CCTU includes CRSs and personnel that have long term and productive involvement with three of the research networks; the fourth-antibacterial resistance-being a new network in this consortium. The CRSs and their network affiliations include: Northwestern University (adult HIV therapeutic strategies); University of Illinois Chicago (vaccines to prevent HIV, integrated HIV prevention). Rush University (adult HIV therapeutic strategies), University of Chicago (integrated HIV prevention strategies) and Trinity Health & Wellness Center (adult HIV therapeutic strategies). Four of the CRSs are located in Chicago, an ethnically and racially diverse urban area of 9.5 million persons that is the third largest metropolitan region in the United States and one of the major urban HIV epicenters. The aims of this proposal are: development, implementation and adaptation of the clinical research program of the 1) Adult HIV Therapeutics Strategy, Network, 2) the Vaccines to Prevent HIV Network, 3) the Integrated HIV Prevention Strategies Network, and 4) Bidirectional, engagement of the relevant and at risk HIV-infected/impacted communities with the CCTU clinical researchers. The CCTU is well positioned to reach diverse populations and contribute significantly to the NIAID research agenda. RELEVANCE: The phenomenal scientific advances in HIV/AIDS research over the past 30 years have in large part been due to NIAID's high-impact therapeutic and prevention studies being performed by its clinical trials units (CTUs). The Chicago CTU will continue to respond rapidly to emerging clinical research needs, engage constituents, and identify more effective treatment and prevention strategies.